Nivolumab plus ipilimumab in non-small-cell lung cancer

Juwon Kim; Sang W. Shin

doi:10.1056/NEJMc1916859

Nivolumab plus ipilimumab in non-small-cell lung cancer

Juwon Kim
, Sang W. Shin

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	874
Number of pages	1
Journal	New England Journal of Medicine
Volume	382
Issue number	9
DOIs	https://doi.org/10.1056/NEJMc1916859
Publication status	Published - 2020 Feb 27

Bibliographical note

Funding Information:
Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported.

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMc1916859

Cite this

@article{04dc4a9383a9438abf9b31f97177f91b,

title = "Nivolumab plus ipilimumab in non-small-cell lung cancer",

author = "Juwon Kim and Shin, \{Sang W.\}",

note = "Funding Information: Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported.",

year = "2020",

month = feb,

day = "27",

doi = "10.1056/NEJMc1916859",

language = "English",

volume = "382",

pages = "874",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "9",

}

TY - JOUR

T1 - Nivolumab plus ipilimumab in non-small-cell lung cancer

AU - Kim, Juwon

AU - Shin, Sang W.

N1 - Funding Information: Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported.

PY - 2020/2/27

Y1 - 2020/2/27

UR - https://www.scopus.com/pages/publications/85080050446

U2 - 10.1056/NEJMc1916859

DO - 10.1056/NEJMc1916859

M3 - Article

C2 - 32101672

AN - SCOPUS:85080050446

SN - 0028-4793

VL - 382

SP - 874

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 9

ER -

Nivolumab plus ipilimumab in non-small-cell lung cancer

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this